OUTLOOK THERAPEUTICS, INC.
BiotechOUTLOOK THERAPEUTICS, INC. is a biotechnology company focused on Immunology, Ophthalmology, Dermatology.
OUTLOOK THERAPEUTICS, INC. at a Glance
- Strong track record with 80% execution quality across 5 trials
- Fast trial execution (17 months median completion)
OUTLOOK THERAPEUTICS, INC.'s Key Drugs
OUTLOOK THERAPEUTICS, INC.'s core commercial portfolio centers on LYTENAVA, spanning Immunology and Ophthalmology — its most strategically important drugs approved in the last 15 years.
OUTLOOK THERAPEUTICS, INC.'s Recent FDA Approvals
OUTLOOK THERAPEUTICS, INC. secured 1 new FDA approval for novel drugs (NDA/BLA) in the last two years.
OUTLOOK THERAPEUTICS, INC.'s Therapeutic Areas
OUTLOOK THERAPEUTICS, INC.'s approved drugs and pipeline span 3 therapeutic areas, led by Immunology and Ophthalmology. Weighted by commercial stage — approved drugs count most, then late-stage trials.
OUTLOOK THERAPEUTICS, INC.'s Top Competitors
OUTLOOK THERAPEUTICS, INC.'s closest competitors by therapeutic-area and drug-target overlap include BAUSCH, BAUSCH AND LOMB INC, and Pfizer. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
OUTLOOK THERAPEUTICS, INC. Pipeline Snapshot
OUTLOOK THERAPEUTICS, INC. has 20 active clinical programs from ClinicalTrials.gov — 12 Phase 3, 8 Phase 2 and 0 Phase 1.
Phase 3 Readout Calendar Pro
1 Phase 3 trial with confidence-graded primary completion dates.
Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • LYTENAVA leads revenue
- • Drug-level revenue analysis
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Execution Intelligence
- • Phase 3: 4/5 completed
- • Speed: 17 months avg
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (0)
Company Info
- First Approval
- 2026-07-24
- Latest
- 2026-07-24
- Applications
- 1
How We Calculate These Metrics
Execution Quality Score
Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.
What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Excellent (80%+): Top-tier execution, most trials reach planned endpoints
- Good (60-79%): Strong execution with occasional early terminations
- Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
- Needs Improvement (under 40%): High termination rates, execution challenges